Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1988 Feb;32(2):231–235. doi: 10.1128/aac.32.2.231

Development of beta-lactam resistance and increased quinolone MICs during therapy of experimental Pseudomonas aeruginosa endocarditis.

A S Bayer 1, L Hirano 1, J Yih 1
PMCID: PMC172140  PMID: 3129985

Abstract

The in vivo efficacies of pefloxacin, a new fluoroquinolone, and amikacin-ceftazidime were compared in 50 rabbits with experimental aortic endocarditis caused by Pseudomonas aeruginosa. Animals were randomly chosen to receive 4 or 10 days of no therapy (controls), pefloxacin (40 mg/kg [body weight] per day, intramuscularly [i.m.]), or amikacin (30 or 80 mg/kg per day, i.m.)-ceftazidime (150 mg/kg per day, i.m.). Pefloxacin and both amikacin regimens significantly reduced vegetation bacterial densities compared with controls at days 4 and 10 of treatment (P less than 0.0005). By day 10 of therapy, between 33 and 40% of vegetations from amikacin-ceftazidime recipients contained ceftazidime-resistant bacteria (MICs, greater than 25 micrograms/ml); nitrocefin agar overlay confirmed that these ceftazidime-resistant variants were constitutive overproducers of beta-lactamase. At therapy days 4 and 10, approximately 30% of vegetations sampled from pefloxacin recipients contained bacteria for which pefloxacin MICs were four- to eightfold higher than the MIC for the parental strain used to initially induce endocarditis (MIC, 0.19 microgram/ml). These variants also exhibited increases in ciprofloxacin and ticarcillin MICs, as well as pleotropic resistance to chloramphenicol (but not to amikacin, ceftazidime, or tetracycline). Amikacin-ceftazidime, as well as pefloxacin, was effective in this model of aortic pseudomonal endocarditis. However, in vivo development of ceftazidime resistance and step-ups in pefloxacin MICs among intravegetation isolates were associated with inability to completely eradicate P. aeruginosa from aortic vegetations.

Full text

PDF
231

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Archer G., Fekety F. R. Experimental endocarditis due to Pseudomonas aeruginosa. I. Description of a model. J Infect Dis. 1976 Jul;134(1):1–7. doi: 10.1093/infdis/134.1.1. [DOI] [PubMed] [Google Scholar]
  2. Auckenthaler R., Michéa-Hamzehpour M., Pechère J. C. In-vitro activity of newer quinolones against aerobic bacteria. J Antimicrob Chemother. 1986 Apr;17 (Suppl B):29–39. doi: 10.1093/jac/17.suppl_b.29. [DOI] [PubMed] [Google Scholar]
  3. Bayer A. S., Blomquist I. K., Kim K. S. Ciprofloxacin in experimental aortic valve endocarditis due to Pseudomonas aeruginosa. J Antimicrob Chemother. 1986 May;17(5):641–649. doi: 10.1093/jac/17.5.641. [DOI] [PubMed] [Google Scholar]
  4. Bayer A. S., Lam K., Norman D., Kim K. S., Morrison J. O. Amikacin + ceftazidime therapy of experimental right-sided Pseudomonas aeruginosa endocarditis in rabbits. Chemotherapy. 1985;31(5):351–361. doi: 10.1159/000238359. [DOI] [PubMed] [Google Scholar]
  5. Bayer A. S., Lindsay P., Yih J., Hirano L., Lee D., Blomquist I. K. Efficacy of ciprofloxacin in experimental aortic valve endocarditis caused by a multiply beta-lactam-resistant variant of Pseudomonas aeruginosa stably derepressed for beta-lactamase production. Antimicrob Agents Chemother. 1986 Oct;30(4):528–531. doi: 10.1128/aac.30.4.528. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bayer A. S., Norman D., Kim K. S. Efficacy of amikacin and ceftazidime in experimental aortic valve endocarditis due to Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1985 Dec;28(6):781–785. doi: 10.1128/aac.28.6.781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bayer A. S., Peters J., Parr T. R., Jr, Chan L., Hancock R. E. Role of beta-lactamase in in vivo development of ceftazidime resistance in experimental Pseudomonas aeruginosa endocarditis. Antimicrob Agents Chemother. 1987 Feb;31(2):253–258. doi: 10.1128/aac.31.2.253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Carrizosa J., Kaye D. Antibiotic synergism in enterococcal endocarditis. J Lab Clin Med. 1976 Jul;88(1):132–141. [PubMed] [Google Scholar]
  9. Chalkley L. J., Koornhof H. J. Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions. Antimicrob Agents Chemother. 1985 Aug;28(2):331–342. doi: 10.1128/aac.28.2.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Chambers H. F., Hackbarth C. J., Drake T. A., Rusnak M. G., Sande M. A. Endocarditis due to methicillin-resistant Staphylococcus aureus in rabbits: expression of resistance to beta-lactam antibiotics in vivo and in vitro. J Infect Dis. 1984 Jun;149(6):894–903. doi: 10.1093/infdis/149.6.894. [DOI] [PubMed] [Google Scholar]
  11. Choi C., Bayer A. S., Fujita N. K., Lam K., Guze L. B., Yoshikawa T. T. Therapy of experimental Pseudomonas endocarditis with high-dose amikacin and ticarcillin. Chemotherapy. 1983;29(4):303–312. doi: 10.1159/000238213. [DOI] [PubMed] [Google Scholar]
  12. Durack D. T., Beeson P. B. Experimental bacterial endocarditis. II. Survival of a bacteria in endocardial vegetations. Br J Exp Pathol. 1972 Feb;53(1):50–53. [PMC free article] [PubMed] [Google Scholar]
  13. Fass R. J. In vitro activity of ciprofloxacin (Bay o 9867). Antimicrob Agents Chemother. 1983 Oct;24(4):568–574. doi: 10.1128/aac.24.4.568. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Frydman A. M., Le Roux Y., Lefebvre M. A., Djebbar F., Fourtillan J. B., Gaillot J. Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers. J Antimicrob Chemother. 1986 Apr;17 (Suppl B):65–79. doi: 10.1093/jac/17.suppl_b.65. [DOI] [PubMed] [Google Scholar]
  15. Gootz T. D., Sanders C. C., Goering R. V. Resistance to cefamandole: derepression of beta-lactamases by cefoxitin and mutation in Enterobacter cloacae. J Infect Dis. 1982 Jul;146(1):34–42. doi: 10.1093/infdis/146.1.34. [DOI] [PubMed] [Google Scholar]
  16. Hirai K., Aoyama H., Suzue S., Irikura T., Iyobe S., Mitsuhashi S. Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12. Antimicrob Agents Chemother. 1986 Aug;30(2):248–253. doi: 10.1128/aac.30.2.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hooper D. C., Wolfson J. S., Ng E. Y., Swartz M. N. Mechanisms of action of and resistance to ciprofloxacin. Am J Med. 1987 Apr 27;82(4A):12–20. [PubMed] [Google Scholar]
  18. Hooper D. C., Wolfson J. S., Souza K. S., Tung C., McHugh G. L., Swartz M. N. Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli. Antimicrob Agents Chemother. 1986 Apr;29(4):639–644. doi: 10.1128/aac.29.4.639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Jimenez-Lucho V. E., Saravolatz L. D., Medeiros A. A., Pohlod D. Failure of therapy in pseudomonas endocarditis: selection of resistant mutants. J Infect Dis. 1986 Jul;154(1):64–68. doi: 10.1093/infdis/154.1.64. [DOI] [PubMed] [Google Scholar]
  20. Naraqi S., Kirkpatrick G. P., Kabins S. Relapsing pneumococcal meningitis: isolation of an organism with decreased susceptibility to penicillin G. J Pediatr. 1974 Nov;85(5):671–673. doi: 10.1016/s0022-3476(74)80513-5. [DOI] [PubMed] [Google Scholar]
  21. Parrillo J. E., Borst G. C., Mazur M. H., Iannini P., Klempner M. S., Moellering R. C., Jr, Anderson S. E. Endocarditis due to resistant viridans streptococci during oral penicillin chemoprophylaxis. N Engl J Med. 1979 Feb 8;300(6):296–300. doi: 10.1056/NEJM197902083000608. [DOI] [PubMed] [Google Scholar]
  22. Quinn J. P., Dudek E. J., DiVincenzo C. A., Lucks D. A., Lerner S. A. Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J Infect Dis. 1986 Aug;154(2):289–294. doi: 10.1093/infdis/154.2.289. [DOI] [PubMed] [Google Scholar]
  23. Rella M., Haas D. Resistance of Pseudomonas aeruginosa PAO to nalidixic acid and low levels of beta-lactam antibiotics: mapping of chromosomal genes. Antimicrob Agents Chemother. 1982 Aug;22(2):242–249. doi: 10.1128/aac.22.2.242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Reyes M. P., Lerner A. M. Current problems in the treatment of infective endocarditis due to Pseudomonas aeruginosa. Rev Infect Dis. 1983 Mar-Apr;5(2):314–321. doi: 10.1093/clinids/5.2.314. [DOI] [PubMed] [Google Scholar]
  25. Sande M. A., Johnson M. L. Antimicrobial therapy of experimental endocarditis caused by Staphylococcus aureus. J Infect Dis. 1975 Apr;131(4):367–375. doi: 10.1093/infdis/131.4.367. [DOI] [PubMed] [Google Scholar]
  26. Sanders C. C., Sanders W. E., Jr, Goering R. V. Overview of preclinical studies with ciprofloxacin. Am J Med. 1987 Apr 27;82(4A):2–11. [PubMed] [Google Scholar]
  27. Scully B. E., Nakatomi M., Ores C., Davidson S., Neu H. C. Ciprofloxacin therapy in cystic fibrosis. Am J Med. 1987 Apr 27;82(4A):196–201. [PubMed] [Google Scholar]
  28. Thabaut A., Durosoir J. L. Activité antibactérienne comparée in vitro de la péfloxacine (1589 RB), de l'acide nalidixique, de l'acide pipémidique et de la fluméquine. Pathol Biol (Paris) 1982 Jun;30(6):394–397. [PubMed] [Google Scholar]
  29. Zeiler H. J. Evaluation of the in vitro bactericidal action of ciprofloxacin on cells of Escherichia coli in the logarithmic and stationary phases of growth. Antimicrob Agents Chemother. 1985 Oct;28(4):524–527. doi: 10.1128/aac.28.4.524. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES